ReviewFrontiers in medicine2026
MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is characterized by the dual pathology of peripheral immune-mediated platelet clearance and restricted platelet production by megakaryocytes. The TPO-MPL axis is a central regulator of platelet homeostasis, and ligand-induced receptor activation is associated with downstream JAK2-STAT, MAPK, and PI3K-AKT signaling. This review summarizes the structural and functional features of TPO and MPL, the major immunopathogenic mechanisms of ITP, and the current clinical use of thrombopoietin receptor agonists (TPO-RAs) in ITP. Recent structural and functional studies suggest that TPO-RAs with distinct binding sites may not engage MPL in fully identical ways and may therefore be associated with differences in receptor conformation, dimer geometry, and downstream signaling output. Within this emerging structural and functional framework, these structural and signaling differences may help explain response heterogeneity and the clinical observation that some patients may still benefit after switching agents. However, direct experimental evidence linking switching outcomes to specific alterations in MPL dimer geometry remains lacking, and the available clinical evidence regarding switching comes mainly from retrospective and observational studies, with additional support from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.